0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no

Transcription

1 Natl Med J China, December 10,2003,Vol 83, No (CIK ), T, CIK 13 (PBMC),, ;CIK, (DC1) (CD2),CD3 + CD8 +, CD3 + CD56 +, CD25 +, 3315 % 1011 % 717 % 218 %1213 % 415 %,3616 % 910 % 1819 % 619 %1614 % 519 %, CD3 + CD8 +,CD25 + CD3 + CD CD3 + CD4 + NK, CIKDC1 CD2,0159 % 0123 % 0126 % 0112 %0185 % 0127 %0143 % 0120 %CIK, CIK, ; ;,; Identification of immunological effector cells after autologous cytokine2induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients SHI Ming, ZHANG Bing, TANG Zi2rong, L EI Zhou2yun, WANG Hui2fen, FENG Yong2yi, LIU Jin2chao, FAN Zhen2ping, LI Han2wei, MU Jin2song, WANG Fu2sheng1 Division of Biological Engineering, Beijing Institute of Infectious Disease, the 302 Hospital of PLA, Beijing , China Corresponding author : WANG Fu2sheng Abstract Objective To investigate the alteration of the cellular profiles of T lymphocyte subsets and dendritic cell subsets in peripheral blood of primary hepatocellular carcinoma ( HCC) patients after being transfused with autologous cytokine2induced killer cells (CIK) in patients, then to evaluate the clinical efficacy of the immune therapeutic strategy1 Methods Peripheral blood mononuclear cells (PBMCs) from 13 patients with primary were collected using blood cell separator, and expanded in the fresh AIM2V medium in the presence of cytokine cocktail including interferon2gamma ( IFN2 ), monoclonal antibody (mab) against CD3 and interleukin22 ( IL22) 1 The phenotypic patterns of CIK cells were longitudinally characterized by flow cytometry on day 0, 4, 7, 10,13 and 15 during the incubation period1 PBMCs obtained from HCC patients before or after CIK cells transfusion into bodies to assay the changes of proportion of DC1 or DC2 in peripheral blood1 Results After in vitro incubation for 14 or 15 days, a large of CD3 + CD56 + cells were produced from their progenitors and the percentages of CD3 + CD8 +, CD3 + CD56 +,CD25 + cells significantly increased from 3315 % 1011 %, 717 % 218 %, and 1213 % 415 % at the beginning to 3616 % 910 % ( P < 0105), 1819 % 619 % ( P < 0101), and 1614 % 519 % ( P < 0105) at the day 15, respectively1 In contrast, the percentages of CD3 + CD4 + and NK cells displayed no significant difference1 The percentages of CD3 +, CD3 + CD8 + cells was held at a higher level during the whole incubation period, however those of the CD25 +, and CD3 + CD56 + cells began decreasing on day 7 and day 13, respectively1 The proportion of type of dendritic cells (DC1) and type of dendritic cells (DC2) subsets increased from 0159 % 0123 % and 0126 % 0112 % before CIK cell transfusion to 0185 % 0127 % and 0143 % 0120 % (all P < 0101) after CIK cell transfusion1 The symptom of HCC patients receiving the CIK cell therapy was markedly ameliorated, and not side effect was seen in the treatment1 Conclusion Our results indicated that autologous CIK cells is able to boost the cellular immunological function in HCC patients, which :100039, :

2 Natl Med J China, December 10,2003,Vol 83, No. 23 probably provide a potent immune therapeutic strategy for HCC patients1 Key words Killer cells ; Phenotype ; Carcinoma, hepatocellular ; Dendritic cells (adaptive immunity) (innate immunity) [1 ],,,, (cytokine2induced killer, CIK),CD3 + CD56 +, MHC [2 ],,CIK, [326 ] (dendritic cell, DC),,, T, (adaptive immunity) [7 ] DC, DC1 DC2DC1 ;DC2 ( IFN),, [8,9 ],(good practice in the manufacturing and quality control of drug, or good manufacturing practice, GMP) CIK, CIK, CIK DC1 DC2, CIK 1. : 13, 2, 11,, 47 8 (2966 ), 12, 1 2. : ( GIBCO ) ; IL22 ( ) ;anti2cd3mcab ( ) ;rhifn2( ) ; T ( BD ) ; Spectra 611 ( COBE ) ; ( FACSCalibur, BD ), CellQuest, SimulSET, MultiSET, FACSCOMP 1. CIK: CIK GMP, GMP, (Spectra v 611) (peripheral blood mononuclear cell, PBMC), (14) 10 9, 4070 ml GMP, (l2) 10 6 Πml,,,37,5 % CO CIK :CIK 10 3, 1Π3 CIK, ml CIK, 3. T :CIK 810,5 ml, T, DC1 DC2 4. : (1) : ; (2) : ; (3) : ; (4) : 5 HBV DNA ; (5) : DC ; (6) : CT B : 6 : 2 3 : 6 5. :gx s,spss, 1. :

3 Natl Med J China, December 10,2003,Vol 83, No ,CD3 + T,,CD3 + CD4 +,CD3 + CD8 +,CD25 +, 7, ( 1) CD3 + CD56 +, 13, (2) 1 2. CIK: T DC1Π DC2 CIK 8 10 d, CD3 + CD8 + CD3 + CD56 + CD25 +, 3315 % 1011 % 717 % 218 % 1213 % 415 %, 3616 % 910 % ( P < 0105) 1819 % 619 % ( P < 0101) 1614 % 519 % ( P < 0105) CD3 + CD4 + NK,,1 108 d, 2090 d, 810 d,, CIK 108 d 3. CIK DC :CIKDC1 DC % 0123 %0126 % 0112 %, 0185 % 0127 %0143 % 0120 %, ( P < 0101) CIK DC1 DC2 4. :CIK 3, 9,1 CIK CD3 + CD CD3 + CD56 +

4 Natl Med J China, December 10,2003,Vol 83, No. 23,1 6 CIK,,,,,3 B 5. :6 h,, h, (12Π13), 1,CIK, CIK PBMC CIK,, CD3 + CD56 +, MHC,CIKMHC [10 ],,,, CD8 + T (cytotoxic T lymphocyte,ctl),,cik CD3 + CD %5 % [11 ],,CIK,,CIK CD3 + CD8 + CD3 + CD56 + CD % 717 %1213 %,CIK 3616 % 1819 %1614 %, CD3 + CD8 +, CD25 + CD3 + CD , CD3 + CD4 + NK, ( P > 0105), 10,,, [3 ],,, DC [12,13 ] DC, T, CIK DC1 DC2, 0159 %0126 % 0185 %0143 % ( P < 0101) CIK,DC1 DC2, DC1 DC2,, DC1 DC2,, CTL, CIK, DC, CIK [14,15 ],CIK DC,CIK, DC [16 ], CIKDC CIK,CIK, CIK,, CIK, 1 Ladhams A, Schmidt C, Sing G, et al. Treatment of non2resectable hepatocellular carcinoma with autologous tumor2pulsed dendritic cells. J Gastroenterol Hepatol, 2002, 17 : Schmidt2Wolf IGH, Lefterova P, Johnston V, et al. Propagation of T cells with NK cell marker. Br J Haematol, 1994, 87 : Shi M, Lei ZY, Wang FS, et al. Human cytokine2induced killer cells inhibit the growth of hepatocellular carcinoma cells transplanted in nude mice. Chin J Cancer Biother, 2002, 9 : Wang FS, Liu MX, Zhang B, et al. Antitumor activities of human autologous cytokine2induced killer ( CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol, 2002, 8 : Du QY, Liu MX, Wang FS, et al. The effect of CIK against hepatocellular carcinoma cells in vivo or ex vivo. Chin J Cancer, 2001, 11 : Du QY, Wang FS, Xu DP, et al. Cytotoxic effects of CIK against hepatocellular carcinoma cells in vitrol. World Chin J Digestol, 2000, 8 : Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol, 2000,18 :

5 Natl Med J China, December 10,2003,Vol 83, No Kunitani H, Shimizu Y, Murata H, et al. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J Hepatol, 2002, 36 : Hiasa Y, Akbar SM, Abe M, et al. Dendritic cell subtypes in autoimmune liver diseases ; decreased expression of HLA DR and CD123 on type 2 dendritic cells. Hepatol Res, 2002, 22 : Baxevanis CN, Gritzapis AD, Tsitsilonis OE, et al. HER22Πneu2derived peptide epitopes are also recognized by cytotoxic CD3 ( + ) CD56 ( + ) (natural killer T) lymphocytes. Int J Cancer,2002, 98 : Lu PH, Negrin RS. A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo anti2tumor activity in mice with potent severe combined immunodeficiency. J Immunol, 1994, 153 : Xing LH, Wang FS, Liu MX, et al. Property and implication of dendritic cells from peripheral blood monocytes in patients with persistent hepatitis B virus infection. Chin J Infect Dis, 2001,19 : Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med, 1998, 188 : Marten A, Renoth S, von Lilienfeld2Toal M, et al. Enhanced lytic activity of cytokine2induced killer cells against multiple myeloma cells after co2culture with idiotype2pulsed dendritic cells. Haematologica, 2001,86 : Ziske C, Marten A, Schottker B, et al. Resistance of pancreatic carcinoma cells is reversed by coculturing NK2like T cells with dendritic cells pulsed with tumor2derived RNA and CA Mol Ther, 2001,3 : Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine2 induced killer cells lead to an activation of both populations. J Immunother, 2001, 24 : ( : ) ( :), ,,,,,,, : (1),, (2),, (3), 11 : (1), (2) (3),, (4) (5),, Π 21 :, : ( ) () :,,,, : (1), ; (2), ; (3), ; (4) ; (5),; (6),; (7) ,,, ,,,,, 24,X CT,,,,,,400